HALO - Halozyme Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Halozyme Therapeutics, Inc.

11388 Sorrento Valley Road
San Diego, CA 92121
United States
858-794-8889
http://www.halozyme.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees281

Key Executives

NameTitlePayExercisedYear Born
Dr. Helen I. TorleyPres, CEO & Director1.57MN/A1963
Ms. Laurie D. StelzerSr. VP & CFO802.9kN/A1968
Mr. Harry J. LeonhardtSr. VP, Gen. Counsel & Corp. Sec.757.57kN/A1957
Dr. Dimitrios ChondrosChief Medical Officer & Sr. VP937.77kN/A1965
Mr. Benjamin J. HickeySr. VP & Chief Commercial Officer828.89kN/A1975
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to enhance resorption of radiopaque agents. The company also develops PEGPH20, a therapy that is in Phase III clinical trial for pancreatic ductal adenocarcinoma; in Phase Ib clinical trial for non-small cell lung cancer; in Phase Ib/II clinical trial for patients with previously treated metastatic pancreatic ductal adenocarcinoma; in Phase Ib/II clinical trial for patients with gastric cancer; and in Phase Ib/II for cholangiocarcinoma and gall bladder cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. The company was founded in 1998 and is headquartered in San Diego, California.

Corporate Governance

Halozyme Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 3. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 5; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.